Nanox to integrate Ambra Health's medical image management software; ACTO acquires CoHealth's content delivery app; and more digital health deals

Also: Vocalis Health and Mayo Clinic seek new pulmonary hypertension biomarkers; Sensyne Health and Microsoft's strategic partnership focuses on clinical AI co-development.
By Dave Muoio
03:17 pm
Paperwork is handed off between two people

This morning Israeli "Digital X-ray" company Nanox announced a new deal with medical data and image management firm Ambra Health. The agreement will see Ambra's cloud software integrated with the digital component of Nanox's in-development imaging systems, and according to the companies will streamline image management while making it easier to access for providers and patients.

"It is our intent to provide seamless image exchange once our systems are approved by the FDA and we commence deployments. By working with Ambra, we can directly connect our modalities at hospitals with imaging providers with minimal integration effort and a high level of data-privacy,” Ran Poliakine, founder and CEO of Nanox, said in a statement.

ACTO, a life sciences education and engagement platform, announced this morning that it has acquired health content delivery mobile app CoHealth. The terms of the deal were not disclosed.

Designed for use by patients and caregivers, CoHealth's tool has worked with more than 200 health organizations to provide medical information throughout an individual's healthcare journey. ACTO plans to integrate the offering with its own business, which disseminates its information to a variety of stakeholders alongside patients, such as physicians or field representatives.

“By joining the ACTO family, we are taking the next step toward our vision of connecting the dots in healthcare,” CoHealth CEO Zack Fisch Rothbart said in a statement. “ACTO’s world-class platform in life sciences education and engagement, combined with CoHealth’s expertise and technology surrounding the delivery of trusted health content, will create a ‘single source of truth’ for patients to access the right information whenever and wherever they need it.” 

Artificial intelligence and vocal biomarker company Vocalis Health has launched a research collaboration with the Mayo Clinic that seeks to develop new screening, detection and health monitoring tools. To start, the partners will be working to identify vocal biomarkers for pulmonary hypertension. Mayo Clinic will be running a prospective clinical validation study that employs Vocalis' proprietary voice analysis technology.

“Voice analysis has the potential to help physicians make more informed decisions about their patients in a non-invasive, cost-effective manner," Vocalis CEO Tal Wenderow said in a statement. "We believe this technology could have important clinical implications for telemedicine and remote patient monitoring in the very near future. We are excited to work with Mayo Clinic and have already started planning clinical trials for additional indications.”

U.K. clinical artificial intelligence Sensyne Health has expanded its strategic partnership with Microsoft. Sensyne said the co-development deal will help scale and refine its technology, provide the company with earlier access to Microsoft's tools, and promote Sensyne's products across Microsoft's marketing channels.

“This strategic partnership with Microsoft will further enhance Sensyne’s ability to advance and scale the benefits that advanced clinical AI can bring to improve patient outcomes and accelerate the development of new medicines through its research partnerships with NHS Trusts," Sensyne Health CEO Lord Paul Drayson said in a statement.

Machine learning drug discovery and development startup insitro announced last week that it has purchased Haystack Sciences, another company focused on data-driven discovery of optimized drug candidates.

While the financial terms of the deal were not disclosed, insitro said that it's looking to leverage Haystack's team and DNA-encoded library technology as it builds new machine learning models focused on small molecules and molecular structure-based predictions of drug activity.

“For the past two years, insitro has been building a company focused on the creation of predictive cell-based models of disease in order to enable the discovery of novel targets and evaluate the benefits of new or existing molecules in genetically defined patient segments," Daphne Koller, CEO and founder of insitro, said in a statement. "This acquisition enables us to expand our capabilities to the area of therapeutic design and advances us towards our goal of leveraging machine learning across the entire process of designing and developing better medicines for patients.”


The latest news in digital health delivered daily to your inbox.

Thank you for subscribing!
Error! Something went wrong!